Turn Therapeutics Inc.
TTRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTurn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company carries a $297.6M market cap, placing it firmly in the micro-cap category. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Market Cap
$297.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-65.33
EPS (TTM)
$-0.28
EPS (Fwd)
$-0.15
ROE
-686.3%
ROA
-50.3%
Cash
$10.3M
Total Debt
$6.1M
Free CF
$4.2M
52W Change
43.9%
Annual Financials
Cash vs Debt
Where TTRX stands vs its 150-day and 200-day moving averages
As of the August 20, 2026 close, TTRX finished 81.85% above its 150-day moving average ($5.40) and 97.19% above its 200-day moving average ($4.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TTRX overbought or oversold?
At the August 20, 2026 close, TTRX's RSI(14) was 63.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $10.3M in cash comfortably exceeding the $6.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $4.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -686.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
As with any equity investment, TTRX carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Turn Therapeutics Inc.'s trajectory.